ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism
Sodium levothyroxine (LT4) as a monotherapy represents the mainstay of treatment of hypothyroidism, and its use has increased over time. Nevertheless, it faces several potential barriers in its ‘real life’ utilization, and hence its clinical effectiveness may be marred. This is suggested by the freq...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2025-07-01
|
| Series: | European Thyroid Journal |
| Subjects: | |
| Online Access: | https://etj.bioscientifica.com/view/journals/etj/14/4/ETJ-25-0123.xml |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850038195845070848 |
|---|---|
| author | Marco Centanni Leonidas Duntas Ulla Feldt-Rasmussen Josef Koehrle Robin P Peeters Salman Razvi Pierpaolo Trimboli Camilla Virili |
| author_facet | Marco Centanni Leonidas Duntas Ulla Feldt-Rasmussen Josef Koehrle Robin P Peeters Salman Razvi Pierpaolo Trimboli Camilla Virili |
| author_sort | Marco Centanni |
| collection | DOAJ |
| description | Sodium levothyroxine (LT4) as a monotherapy represents the mainstay of treatment of hypothyroidism, and its use has increased over time. Nevertheless, it faces several potential barriers in its ‘real life’ utilization, and hence its clinical effectiveness may be marred. This is suggested by the frequent situation of patients failing to reach the therapeutic goals of symptom relief and serum TSH control. Thus, an expert task force was approved by the Guidelines Board of the European Thyroid Association to examine the available data and to formulate recommendations based on the available evidence and the experts’ deduction. The task force provides a body of suggestions to optimize the levothyroxine treatment in monotherapy, considering the key point in the individualization of treatment. Furthermore, the nutritional, pharmacological and pathological factors, potentially leading to the increased need for levothyroxine, are discussed, with a specific focus on the use of liquid and softgel formulations of the hormone. |
| format | Article |
| id | doaj-art-11e71fd24e8f493cb7db3aa26ebbfcfa |
| institution | DOAJ |
| issn | 2235-0802 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | European Thyroid Journal |
| spelling | doaj-art-11e71fd24e8f493cb7db3aa26ebbfcfa2025-08-20T02:56:39ZengBioscientificaEuropean Thyroid Journal2235-08022025-07-0114410.1530/ETJ-25-01231ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidismMarco Centanni0Leonidas Duntas1Ulla Feldt-Rasmussen2Josef Koehrle3Robin P Peeters4Salman Razvi5Pierpaolo Trimboli6Camilla Virili7Sapienza University of Rome, Clinical Endocrinology Unit, AUSL Latina, Latina, ItalyEvgenideion Hospital, Unit of Endocrinology, Metabolism and Diabetes, University of Athens, Athens, GreeceDepartment of Nephrology and Endocrinology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkInstitut für Experimentelle Endokrinologie, Charité Universitätsmedizin Berlin, Berlin, GermanyDepartment of Internal Medicine, Erasmus University Medical Center, Rotterdam, NetherlandsInstitute of Translational and Clinical Research, Newcastle University, Centre for Life, Newcastle upon Tyne, UKThyroid Unit, Clinic for Endocrinology and Diabetology, Ente Ospedaliero Cantonale, Bellinzona, SwitzerlandSapienza University of Rome, Department of Medical-Surgical Sciences and Biotechnologies, Latina, ItalySodium levothyroxine (LT4) as a monotherapy represents the mainstay of treatment of hypothyroidism, and its use has increased over time. Nevertheless, it faces several potential barriers in its ‘real life’ utilization, and hence its clinical effectiveness may be marred. This is suggested by the frequent situation of patients failing to reach the therapeutic goals of symptom relief and serum TSH control. Thus, an expert task force was approved by the Guidelines Board of the European Thyroid Association to examine the available data and to formulate recommendations based on the available evidence and the experts’ deduction. The task force provides a body of suggestions to optimize the levothyroxine treatment in monotherapy, considering the key point in the individualization of treatment. Furthermore, the nutritional, pharmacological and pathological factors, potentially leading to the increased need for levothyroxine, are discussed, with a specific focus on the use of liquid and softgel formulations of the hormone.https://etj.bioscientifica.com/view/journals/etj/14/4/ETJ-25-0123.xmllevothyroxine therapyhypothyroidismlevothyroxine malabsorptionlevothyroxine formulationspatient adherence |
| spellingShingle | Marco Centanni Leonidas Duntas Ulla Feldt-Rasmussen Josef Koehrle Robin P Peeters Salman Razvi Pierpaolo Trimboli Camilla Virili ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism European Thyroid Journal levothyroxine therapy hypothyroidism levothyroxine malabsorption levothyroxine formulations patient adherence |
| title | ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism |
| title_full | ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism |
| title_fullStr | ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism |
| title_full_unstemmed | ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism |
| title_short | ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism |
| title_sort | eta guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism |
| topic | levothyroxine therapy hypothyroidism levothyroxine malabsorption levothyroxine formulations patient adherence |
| url | https://etj.bioscientifica.com/view/journals/etj/14/4/ETJ-25-0123.xml |
| work_keys_str_mv | AT marcocentanni etaguidelinesfortheuseoflevothyroxinesodiumpreparationsinmonotherapytooptimizethetreatmentofhypothyroidism AT leonidasduntas etaguidelinesfortheuseoflevothyroxinesodiumpreparationsinmonotherapytooptimizethetreatmentofhypothyroidism AT ullafeldtrasmussen etaguidelinesfortheuseoflevothyroxinesodiumpreparationsinmonotherapytooptimizethetreatmentofhypothyroidism AT josefkoehrle etaguidelinesfortheuseoflevothyroxinesodiumpreparationsinmonotherapytooptimizethetreatmentofhypothyroidism AT robinppeeters etaguidelinesfortheuseoflevothyroxinesodiumpreparationsinmonotherapytooptimizethetreatmentofhypothyroidism AT salmanrazvi etaguidelinesfortheuseoflevothyroxinesodiumpreparationsinmonotherapytooptimizethetreatmentofhypothyroidism AT pierpaolotrimboli etaguidelinesfortheuseoflevothyroxinesodiumpreparationsinmonotherapytooptimizethetreatmentofhypothyroidism AT camillavirili etaguidelinesfortheuseoflevothyroxinesodiumpreparationsinmonotherapytooptimizethetreatmentofhypothyroidism |